Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VBP

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

- PMLiVE

IQWiG passes Boehringer lung cancer drug

Germany’s cost assessor says it can extend life in some patients, but benefit it ‘minor'

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

Fighting talk

One thing that grasps my interest is how society has adopted military style language when talking about cancer

Research Partnership

- PMLiVE

The BMJ weighs in on Avastin/Lucentis debate

The UK’s leading medical journal says Avastin should be used for wet AMD to cut costs

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

- PMLiVE

Bowel Cancer UK launches research initiative

Announcement for its R&D commitment comes during Bowel Cancer Awareness Month

NHS to expand video and email consultation pilots

Move is part of plans to increase patient access to GPs and pharmacists

- PMLiVE

Nurturing innovation in a tough environment

Much has been achieved in the UK in recent years, but the NHS still has a way to go

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

It’s time to get diabetes right

Patients should have access to the right treatment and care, at the right time, says the ABPI Pharmaceutical Diabetes Initiative 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links